Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial
Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2. Methods In the FFCD-0307 study, patients...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Touchefeu, Y. [verfasserIn] Guimbaud, R. [verfasserIn] Louvet, C. [verfasserIn] Dahan, L. [verfasserIn] Samalin, E. [verfasserIn] Barbier, E. [verfasserIn] Le Malicot, K. [verfasserIn] Cohen, R. [verfasserIn] Gornet, J. M. [verfasserIn] Aparicio, T. [verfasserIn] Nguyen, S. [verfasserIn] Azzedine, A. [verfasserIn] Etienne, P. L. [verfasserIn] Phelip, J. M. [verfasserIn] Hammel, P. [verfasserIn] Chapelle, N. [verfasserIn] Sefrioui, D. [verfasserIn] Mineur, L. [verfasserIn] Lepage, C. [verfasserIn] Bouche, O. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Gastric Cancer - Springer-Verlag, 2002, 22(2018), 3 vom: 11. Okt., Seite 577-586 |
|---|---|
| Übergeordnetes Werk: |
volume:22 ; year:2018 ; number:3 ; day:11 ; month:10 ; pages:577-586 |
| Links: |
|---|
| DOI / URN: |
10.1007/s10120-018-0885-z |
|---|
| Katalog-ID: |
SPR009349944 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR009349944 | ||
| 003 | DE-627 | ||
| 005 | 20201124064155.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201005s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10120-018-0885-z |2 doi | |
| 035 | |a (DE-627)SPR009349944 | ||
| 035 | |a (SPR)s10120-018-0885-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Touchefeu, Y. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2. Methods In the FFCD-0307 study, patients were randomly assigned to receive in L1 either epirubicin, cisplatin, and capecitabine (ECX arm) or fluorouracil, leucovorin, and irinotecan (FOLFIRI arm). L2 treatment was predefined (FOLFIRI for the ECX arm and ECX for the FOLFIRI arm). Chi square tests were used to compare the characteristics of patients treated in L2 with those of patients who did not receive L2. Prognostic factors in L2 for progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox model. Results Among 416 patients included, 101/209 (48.3%) patients in the ECX arm received FOLFIRI in L2, and 81/207 (39.1%) patients in the FOLFIRI arm received ECX in L2. Patients treated in L2, compared with those who only received L1 had : a better ECOG score (0–1: 90.4% versus 79.7%; p = 0.0002), more frequent GEJ localization (40.8% versus 27.6%; p = 0.005), and lower platelet count (median: 298000 versus 335000/$ mm^{3} $; p = 0.02). In multivariate analyses, age < 60 years at diagnosis (HR 1.49, 95% CI 1.09–2.03, p = 0.013) and ECOG score 2 before L2 (HR 2.62, 95% CI 1.41–4.84, p = 0.005) were the only significant poor prognostic factors for OS. Conclusion Age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS. | ||
| 650 | 4 | |a Gastric neoplasm |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Survival |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prognosis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Second-line chemotherapy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Guimbaud, R. |e verfasserin |4 aut | |
| 700 | 1 | |a Louvet, C. |e verfasserin |4 aut | |
| 700 | 1 | |a Dahan, L. |e verfasserin |4 aut | |
| 700 | 1 | |a Samalin, E. |e verfasserin |4 aut | |
| 700 | 1 | |a Barbier, E. |e verfasserin |4 aut | |
| 700 | 1 | |a Le Malicot, K. |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, R. |e verfasserin |4 aut | |
| 700 | 1 | |a Gornet, J. M. |e verfasserin |4 aut | |
| 700 | 1 | |a Aparicio, T. |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, S. |e verfasserin |4 aut | |
| 700 | 1 | |a Azzedine, A. |e verfasserin |4 aut | |
| 700 | 1 | |a Etienne, P. L. |e verfasserin |4 aut | |
| 700 | 1 | |a Phelip, J. M. |e verfasserin |4 aut | |
| 700 | 1 | |a Hammel, P. |e verfasserin |4 aut | |
| 700 | 1 | |a Chapelle, N. |e verfasserin |4 aut | |
| 700 | 1 | |a Sefrioui, D. |e verfasserin |4 aut | |
| 700 | 1 | |a Mineur, L. |e verfasserin |4 aut | |
| 700 | 1 | |a Lepage, C. |e verfasserin |4 aut | |
| 700 | 1 | |a Bouche, O. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastric Cancer |d Springer-Verlag, 2002 |g 22(2018), 3 vom: 11. Okt., Seite 577-586 |w (DE-627)SPR009286586 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2018 |g number:3 |g day:11 |g month:10 |g pages:577-586 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10120-018-0885-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2018 |e 3 |b 11 |c 10 |h 577-586 | ||
| author_variant |
y t yt r g rg c l cl l d ld e s es e b eb m k l mk mkl r c rc j m g jm jmg t a ta s n sn a a aa p l e pl ple j m p jm jmp p h ph n c nc d s ds l m lm c l cl o b ob |
|---|---|
| matchkey_str |
touchefeuyguimbaudrlouvetcdahanlsamaline:2018----:rgotcatriptettetdiheodiehmteayoavnegsrcacreutfoteadm |
| hierarchy_sort_str |
2018 |
| publishDate |
2018 |
| allfields |
10.1007/s10120-018-0885-z doi (DE-627)SPR009349944 (SPR)s10120-018-0885-z-e DE-627 ger DE-627 rakwb eng Touchefeu, Y. verfasserin aut Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2. Methods In the FFCD-0307 study, patients were randomly assigned to receive in L1 either epirubicin, cisplatin, and capecitabine (ECX arm) or fluorouracil, leucovorin, and irinotecan (FOLFIRI arm). L2 treatment was predefined (FOLFIRI for the ECX arm and ECX for the FOLFIRI arm). Chi square tests were used to compare the characteristics of patients treated in L2 with those of patients who did not receive L2. Prognostic factors in L2 for progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox model. Results Among 416 patients included, 101/209 (48.3%) patients in the ECX arm received FOLFIRI in L2, and 81/207 (39.1%) patients in the FOLFIRI arm received ECX in L2. Patients treated in L2, compared with those who only received L1 had : a better ECOG score (0–1: 90.4% versus 79.7%; p = 0.0002), more frequent GEJ localization (40.8% versus 27.6%; p = 0.005), and lower platelet count (median: 298000 versus 335000/$ mm^{3} $; p = 0.02). In multivariate analyses, age < 60 years at diagnosis (HR 1.49, 95% CI 1.09–2.03, p = 0.013) and ECOG score 2 before L2 (HR 2.62, 95% CI 1.41–4.84, p = 0.005) were the only significant poor prognostic factors for OS. Conclusion Age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS. Gastric neoplasm (dpeaa)DE-He213 Survival (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Guimbaud, R. verfasserin aut Louvet, C. verfasserin aut Dahan, L. verfasserin aut Samalin, E. verfasserin aut Barbier, E. verfasserin aut Le Malicot, K. verfasserin aut Cohen, R. verfasserin aut Gornet, J. M. verfasserin aut Aparicio, T. verfasserin aut Nguyen, S. verfasserin aut Azzedine, A. verfasserin aut Etienne, P. L. verfasserin aut Phelip, J. M. verfasserin aut Hammel, P. verfasserin aut Chapelle, N. verfasserin aut Sefrioui, D. verfasserin aut Mineur, L. verfasserin aut Lepage, C. verfasserin aut Bouche, O. verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2018), 3 vom: 11. Okt., Seite 577-586 (DE-627)SPR009286586 nnns volume:22 year:2018 number:3 day:11 month:10 pages:577-586 https://dx.doi.org/10.1007/s10120-018-0885-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 22 2018 3 11 10 577-586 |
| spelling |
10.1007/s10120-018-0885-z doi (DE-627)SPR009349944 (SPR)s10120-018-0885-z-e DE-627 ger DE-627 rakwb eng Touchefeu, Y. verfasserin aut Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2. Methods In the FFCD-0307 study, patients were randomly assigned to receive in L1 either epirubicin, cisplatin, and capecitabine (ECX arm) or fluorouracil, leucovorin, and irinotecan (FOLFIRI arm). L2 treatment was predefined (FOLFIRI for the ECX arm and ECX for the FOLFIRI arm). Chi square tests were used to compare the characteristics of patients treated in L2 with those of patients who did not receive L2. Prognostic factors in L2 for progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox model. Results Among 416 patients included, 101/209 (48.3%) patients in the ECX arm received FOLFIRI in L2, and 81/207 (39.1%) patients in the FOLFIRI arm received ECX in L2. Patients treated in L2, compared with those who only received L1 had : a better ECOG score (0–1: 90.4% versus 79.7%; p = 0.0002), more frequent GEJ localization (40.8% versus 27.6%; p = 0.005), and lower platelet count (median: 298000 versus 335000/$ mm^{3} $; p = 0.02). In multivariate analyses, age < 60 years at diagnosis (HR 1.49, 95% CI 1.09–2.03, p = 0.013) and ECOG score 2 before L2 (HR 2.62, 95% CI 1.41–4.84, p = 0.005) were the only significant poor prognostic factors for OS. Conclusion Age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS. Gastric neoplasm (dpeaa)DE-He213 Survival (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Guimbaud, R. verfasserin aut Louvet, C. verfasserin aut Dahan, L. verfasserin aut Samalin, E. verfasserin aut Barbier, E. verfasserin aut Le Malicot, K. verfasserin aut Cohen, R. verfasserin aut Gornet, J. M. verfasserin aut Aparicio, T. verfasserin aut Nguyen, S. verfasserin aut Azzedine, A. verfasserin aut Etienne, P. L. verfasserin aut Phelip, J. M. verfasserin aut Hammel, P. verfasserin aut Chapelle, N. verfasserin aut Sefrioui, D. verfasserin aut Mineur, L. verfasserin aut Lepage, C. verfasserin aut Bouche, O. verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2018), 3 vom: 11. Okt., Seite 577-586 (DE-627)SPR009286586 nnns volume:22 year:2018 number:3 day:11 month:10 pages:577-586 https://dx.doi.org/10.1007/s10120-018-0885-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 22 2018 3 11 10 577-586 |
| allfields_unstemmed |
10.1007/s10120-018-0885-z doi (DE-627)SPR009349944 (SPR)s10120-018-0885-z-e DE-627 ger DE-627 rakwb eng Touchefeu, Y. verfasserin aut Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2. Methods In the FFCD-0307 study, patients were randomly assigned to receive in L1 either epirubicin, cisplatin, and capecitabine (ECX arm) or fluorouracil, leucovorin, and irinotecan (FOLFIRI arm). L2 treatment was predefined (FOLFIRI for the ECX arm and ECX for the FOLFIRI arm). Chi square tests were used to compare the characteristics of patients treated in L2 with those of patients who did not receive L2. Prognostic factors in L2 for progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox model. Results Among 416 patients included, 101/209 (48.3%) patients in the ECX arm received FOLFIRI in L2, and 81/207 (39.1%) patients in the FOLFIRI arm received ECX in L2. Patients treated in L2, compared with those who only received L1 had : a better ECOG score (0–1: 90.4% versus 79.7%; p = 0.0002), more frequent GEJ localization (40.8% versus 27.6%; p = 0.005), and lower platelet count (median: 298000 versus 335000/$ mm^{3} $; p = 0.02). In multivariate analyses, age < 60 years at diagnosis (HR 1.49, 95% CI 1.09–2.03, p = 0.013) and ECOG score 2 before L2 (HR 2.62, 95% CI 1.41–4.84, p = 0.005) were the only significant poor prognostic factors for OS. Conclusion Age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS. Gastric neoplasm (dpeaa)DE-He213 Survival (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Guimbaud, R. verfasserin aut Louvet, C. verfasserin aut Dahan, L. verfasserin aut Samalin, E. verfasserin aut Barbier, E. verfasserin aut Le Malicot, K. verfasserin aut Cohen, R. verfasserin aut Gornet, J. M. verfasserin aut Aparicio, T. verfasserin aut Nguyen, S. verfasserin aut Azzedine, A. verfasserin aut Etienne, P. L. verfasserin aut Phelip, J. M. verfasserin aut Hammel, P. verfasserin aut Chapelle, N. verfasserin aut Sefrioui, D. verfasserin aut Mineur, L. verfasserin aut Lepage, C. verfasserin aut Bouche, O. verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2018), 3 vom: 11. Okt., Seite 577-586 (DE-627)SPR009286586 nnns volume:22 year:2018 number:3 day:11 month:10 pages:577-586 https://dx.doi.org/10.1007/s10120-018-0885-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 22 2018 3 11 10 577-586 |
| allfieldsGer |
10.1007/s10120-018-0885-z doi (DE-627)SPR009349944 (SPR)s10120-018-0885-z-e DE-627 ger DE-627 rakwb eng Touchefeu, Y. verfasserin aut Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2. Methods In the FFCD-0307 study, patients were randomly assigned to receive in L1 either epirubicin, cisplatin, and capecitabine (ECX arm) or fluorouracil, leucovorin, and irinotecan (FOLFIRI arm). L2 treatment was predefined (FOLFIRI for the ECX arm and ECX for the FOLFIRI arm). Chi square tests were used to compare the characteristics of patients treated in L2 with those of patients who did not receive L2. Prognostic factors in L2 for progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox model. Results Among 416 patients included, 101/209 (48.3%) patients in the ECX arm received FOLFIRI in L2, and 81/207 (39.1%) patients in the FOLFIRI arm received ECX in L2. Patients treated in L2, compared with those who only received L1 had : a better ECOG score (0–1: 90.4% versus 79.7%; p = 0.0002), more frequent GEJ localization (40.8% versus 27.6%; p = 0.005), and lower platelet count (median: 298000 versus 335000/$ mm^{3} $; p = 0.02). In multivariate analyses, age < 60 years at diagnosis (HR 1.49, 95% CI 1.09–2.03, p = 0.013) and ECOG score 2 before L2 (HR 2.62, 95% CI 1.41–4.84, p = 0.005) were the only significant poor prognostic factors for OS. Conclusion Age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS. Gastric neoplasm (dpeaa)DE-He213 Survival (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Guimbaud, R. verfasserin aut Louvet, C. verfasserin aut Dahan, L. verfasserin aut Samalin, E. verfasserin aut Barbier, E. verfasserin aut Le Malicot, K. verfasserin aut Cohen, R. verfasserin aut Gornet, J. M. verfasserin aut Aparicio, T. verfasserin aut Nguyen, S. verfasserin aut Azzedine, A. verfasserin aut Etienne, P. L. verfasserin aut Phelip, J. M. verfasserin aut Hammel, P. verfasserin aut Chapelle, N. verfasserin aut Sefrioui, D. verfasserin aut Mineur, L. verfasserin aut Lepage, C. verfasserin aut Bouche, O. verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2018), 3 vom: 11. Okt., Seite 577-586 (DE-627)SPR009286586 nnns volume:22 year:2018 number:3 day:11 month:10 pages:577-586 https://dx.doi.org/10.1007/s10120-018-0885-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 22 2018 3 11 10 577-586 |
| allfieldsSound |
10.1007/s10120-018-0885-z doi (DE-627)SPR009349944 (SPR)s10120-018-0885-z-e DE-627 ger DE-627 rakwb eng Touchefeu, Y. verfasserin aut Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2. Methods In the FFCD-0307 study, patients were randomly assigned to receive in L1 either epirubicin, cisplatin, and capecitabine (ECX arm) or fluorouracil, leucovorin, and irinotecan (FOLFIRI arm). L2 treatment was predefined (FOLFIRI for the ECX arm and ECX for the FOLFIRI arm). Chi square tests were used to compare the characteristics of patients treated in L2 with those of patients who did not receive L2. Prognostic factors in L2 for progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox model. Results Among 416 patients included, 101/209 (48.3%) patients in the ECX arm received FOLFIRI in L2, and 81/207 (39.1%) patients in the FOLFIRI arm received ECX in L2. Patients treated in L2, compared with those who only received L1 had : a better ECOG score (0–1: 90.4% versus 79.7%; p = 0.0002), more frequent GEJ localization (40.8% versus 27.6%; p = 0.005), and lower platelet count (median: 298000 versus 335000/$ mm^{3} $; p = 0.02). In multivariate analyses, age < 60 years at diagnosis (HR 1.49, 95% CI 1.09–2.03, p = 0.013) and ECOG score 2 before L2 (HR 2.62, 95% CI 1.41–4.84, p = 0.005) were the only significant poor prognostic factors for OS. Conclusion Age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS. Gastric neoplasm (dpeaa)DE-He213 Survival (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 Guimbaud, R. verfasserin aut Louvet, C. verfasserin aut Dahan, L. verfasserin aut Samalin, E. verfasserin aut Barbier, E. verfasserin aut Le Malicot, K. verfasserin aut Cohen, R. verfasserin aut Gornet, J. M. verfasserin aut Aparicio, T. verfasserin aut Nguyen, S. verfasserin aut Azzedine, A. verfasserin aut Etienne, P. L. verfasserin aut Phelip, J. M. verfasserin aut Hammel, P. verfasserin aut Chapelle, N. verfasserin aut Sefrioui, D. verfasserin aut Mineur, L. verfasserin aut Lepage, C. verfasserin aut Bouche, O. verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 22(2018), 3 vom: 11. Okt., Seite 577-586 (DE-627)SPR009286586 nnns volume:22 year:2018 number:3 day:11 month:10 pages:577-586 https://dx.doi.org/10.1007/s10120-018-0885-z lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 22 2018 3 11 10 577-586 |
| language |
English |
| source |
Enthalten in Gastric Cancer 22(2018), 3 vom: 11. Okt., Seite 577-586 volume:22 year:2018 number:3 day:11 month:10 pages:577-586 |
| sourceStr |
Enthalten in Gastric Cancer 22(2018), 3 vom: 11. Okt., Seite 577-586 volume:22 year:2018 number:3 day:11 month:10 pages:577-586 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Gastric neoplasm Survival Prognosis Second-line chemotherapy |
| isfreeaccess_bool |
false |
| container_title |
Gastric Cancer |
| authorswithroles_txt_mv |
Touchefeu, Y. @@aut@@ Guimbaud, R. @@aut@@ Louvet, C. @@aut@@ Dahan, L. @@aut@@ Samalin, E. @@aut@@ Barbier, E. @@aut@@ Le Malicot, K. @@aut@@ Cohen, R. @@aut@@ Gornet, J. M. @@aut@@ Aparicio, T. @@aut@@ Nguyen, S. @@aut@@ Azzedine, A. @@aut@@ Etienne, P. L. @@aut@@ Phelip, J. M. @@aut@@ Hammel, P. @@aut@@ Chapelle, N. @@aut@@ Sefrioui, D. @@aut@@ Mineur, L. @@aut@@ Lepage, C. @@aut@@ Bouche, O. @@aut@@ |
| publishDateDaySort_date |
2018-10-11T00:00:00Z |
| hierarchy_top_id |
SPR009286586 |
| id |
SPR009349944 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009349944</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20201124064155.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10120-018-0885-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009349944</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10120-018-0885-z-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Touchefeu, Y.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2. Methods In the FFCD-0307 study, patients were randomly assigned to receive in L1 either epirubicin, cisplatin, and capecitabine (ECX arm) or fluorouracil, leucovorin, and irinotecan (FOLFIRI arm). L2 treatment was predefined (FOLFIRI for the ECX arm and ECX for the FOLFIRI arm). Chi square tests were used to compare the characteristics of patients treated in L2 with those of patients who did not receive L2. Prognostic factors in L2 for progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox model. Results Among 416 patients included, 101/209 (48.3%) patients in the ECX arm received FOLFIRI in L2, and 81/207 (39.1%) patients in the FOLFIRI arm received ECX in L2. Patients treated in L2, compared with those who only received L1 had : a better ECOG score (0–1: 90.4% versus 79.7%; p = 0.0002), more frequent GEJ localization (40.8% versus 27.6%; p = 0.005), and lower platelet count (median: 298000 versus 335000/$ mm^{3} $; p = 0.02). In multivariate analyses, age < 60 years at diagnosis (HR 1.49, 95% CI 1.09–2.03, p = 0.013) and ECOG score 2 before L2 (HR 2.62, 95% CI 1.41–4.84, p = 0.005) were the only significant poor prognostic factors for OS. Conclusion Age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastric neoplasm</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Survival</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Second-line chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guimbaud, R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Louvet, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dahan, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Samalin, E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barbier, E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Le Malicot, K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cohen, R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gornet, J. M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aparicio, T.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nguyen, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Azzedine, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Etienne, P. L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Phelip, J. M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hammel, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chapelle, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sefrioui, D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mineur, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lepage, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bouche, O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Gastric Cancer</subfield><subfield code="d">Springer-Verlag, 2002</subfield><subfield code="g">22(2018), 3 vom: 11. Okt., Seite 577-586</subfield><subfield code="w">(DE-627)SPR009286586</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:3</subfield><subfield code="g">day:11</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:577-586</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10120-018-0885-z</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2018</subfield><subfield code="e">3</subfield><subfield code="b">11</subfield><subfield code="c">10</subfield><subfield code="h">577-586</subfield></datafield></record></collection>
|
| author |
Touchefeu, Y. |
| spellingShingle |
Touchefeu, Y. misc Gastric neoplasm misc Survival misc Prognosis misc Second-line chemotherapy Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial |
| authorStr |
Touchefeu, Y. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR009286586 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial Gastric neoplasm (dpeaa)DE-He213 Survival (dpeaa)DE-He213 Prognosis (dpeaa)DE-He213 Second-line chemotherapy (dpeaa)DE-He213 |
| topic |
misc Gastric neoplasm misc Survival misc Prognosis misc Second-line chemotherapy |
| topic_unstemmed |
misc Gastric neoplasm misc Survival misc Prognosis misc Second-line chemotherapy |
| topic_browse |
misc Gastric neoplasm misc Survival misc Prognosis misc Second-line chemotherapy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Gastric Cancer |
| hierarchy_parent_id |
SPR009286586 |
| hierarchy_top_title |
Gastric Cancer |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR009286586 |
| title |
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial |
| ctrlnum |
(DE-627)SPR009349944 (SPR)s10120-018-0885-z-e |
| title_full |
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial |
| author_sort |
Touchefeu, Y. |
| journal |
Gastric Cancer |
| journalStr |
Gastric Cancer |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
txt |
| container_start_page |
577 |
| author_browse |
Touchefeu, Y. Guimbaud, R. Louvet, C. Dahan, L. Samalin, E. Barbier, E. Le Malicot, K. Cohen, R. Gornet, J. M. Aparicio, T. Nguyen, S. Azzedine, A. Etienne, P. L. Phelip, J. M. Hammel, P. Chapelle, N. Sefrioui, D. Mineur, L. Lepage, C. Bouche, O. |
| container_volume |
22 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Touchefeu, Y. |
| doi_str_mv |
10.1007/s10120-018-0885-z |
| author2-role |
verfasserin |
| title_sort |
prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase iii ffcd-0307 trial |
| title_auth |
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial |
| abstract |
Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2. Methods In the FFCD-0307 study, patients were randomly assigned to receive in L1 either epirubicin, cisplatin, and capecitabine (ECX arm) or fluorouracil, leucovorin, and irinotecan (FOLFIRI arm). L2 treatment was predefined (FOLFIRI for the ECX arm and ECX for the FOLFIRI arm). Chi square tests were used to compare the characteristics of patients treated in L2 with those of patients who did not receive L2. Prognostic factors in L2 for progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox model. Results Among 416 patients included, 101/209 (48.3%) patients in the ECX arm received FOLFIRI in L2, and 81/207 (39.1%) patients in the FOLFIRI arm received ECX in L2. Patients treated in L2, compared with those who only received L1 had : a better ECOG score (0–1: 90.4% versus 79.7%; p = 0.0002), more frequent GEJ localization (40.8% versus 27.6%; p = 0.005), and lower platelet count (median: 298000 versus 335000/$ mm^{3} $; p = 0.02). In multivariate analyses, age < 60 years at diagnosis (HR 1.49, 95% CI 1.09–2.03, p = 0.013) and ECOG score 2 before L2 (HR 2.62, 95% CI 1.41–4.84, p = 0.005) were the only significant poor prognostic factors for OS. Conclusion Age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS. |
| abstractGer |
Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2. Methods In the FFCD-0307 study, patients were randomly assigned to receive in L1 either epirubicin, cisplatin, and capecitabine (ECX arm) or fluorouracil, leucovorin, and irinotecan (FOLFIRI arm). L2 treatment was predefined (FOLFIRI for the ECX arm and ECX for the FOLFIRI arm). Chi square tests were used to compare the characteristics of patients treated in L2 with those of patients who did not receive L2. Prognostic factors in L2 for progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox model. Results Among 416 patients included, 101/209 (48.3%) patients in the ECX arm received FOLFIRI in L2, and 81/207 (39.1%) patients in the FOLFIRI arm received ECX in L2. Patients treated in L2, compared with those who only received L1 had : a better ECOG score (0–1: 90.4% versus 79.7%; p = 0.0002), more frequent GEJ localization (40.8% versus 27.6%; p = 0.005), and lower platelet count (median: 298000 versus 335000/$ mm^{3} $; p = 0.02). In multivariate analyses, age < 60 years at diagnosis (HR 1.49, 95% CI 1.09–2.03, p = 0.013) and ECOG score 2 before L2 (HR 2.62, 95% CI 1.41–4.84, p = 0.005) were the only significant poor prognostic factors for OS. Conclusion Age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS. |
| abstract_unstemmed |
Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2. Methods In the FFCD-0307 study, patients were randomly assigned to receive in L1 either epirubicin, cisplatin, and capecitabine (ECX arm) or fluorouracil, leucovorin, and irinotecan (FOLFIRI arm). L2 treatment was predefined (FOLFIRI for the ECX arm and ECX for the FOLFIRI arm). Chi square tests were used to compare the characteristics of patients treated in L2 with those of patients who did not receive L2. Prognostic factors in L2 for progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox model. Results Among 416 patients included, 101/209 (48.3%) patients in the ECX arm received FOLFIRI in L2, and 81/207 (39.1%) patients in the FOLFIRI arm received ECX in L2. Patients treated in L2, compared with those who only received L1 had : a better ECOG score (0–1: 90.4% versus 79.7%; p = 0.0002), more frequent GEJ localization (40.8% versus 27.6%; p = 0.005), and lower platelet count (median: 298000 versus 335000/$ mm^{3} $; p = 0.02). In multivariate analyses, age < 60 years at diagnosis (HR 1.49, 95% CI 1.09–2.03, p = 0.013) and ECOG score 2 before L2 (HR 2.62, 95% CI 1.41–4.84, p = 0.005) were the only significant poor prognostic factors for OS. Conclusion Age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER |
| container_issue |
3 |
| title_short |
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial |
| url |
https://dx.doi.org/10.1007/s10120-018-0885-z |
| remote_bool |
true |
| author2 |
Guimbaud, R. Louvet, C. Dahan, L. Samalin, E. Barbier, E. Le Malicot, K. Cohen, R. Gornet, J. M. Aparicio, T. Nguyen, S. Azzedine, A. Etienne, P. L. Phelip, J. M. Hammel, P. Chapelle, N. Sefrioui, D. Mineur, L. Lepage, C. Bouche, O. |
| author2Str |
Guimbaud, R. Louvet, C. Dahan, L. Samalin, E. Barbier, E. Le Malicot, K. Cohen, R. Gornet, J. M. Aparicio, T. Nguyen, S. Azzedine, A. Etienne, P. L. Phelip, J. M. Hammel, P. Chapelle, N. Sefrioui, D. Mineur, L. Lepage, C. Bouche, O. |
| ppnlink |
SPR009286586 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s10120-018-0885-z |
| up_date |
2024-07-04T01:41:38.274Z |
| _version_ |
1803610801596006401 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009349944</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20201124064155.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10120-018-0885-z</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009349944</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10120-018-0885-z-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Touchefeu, Y.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim The aim of this study was to determine prognostic factors in patients treated with second-line therapy (L2) for locally advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma in a randomized phase III study with predefined L2. Methods In the FFCD-0307 study, patients were randomly assigned to receive in L1 either epirubicin, cisplatin, and capecitabine (ECX arm) or fluorouracil, leucovorin, and irinotecan (FOLFIRI arm). L2 treatment was predefined (FOLFIRI for the ECX arm and ECX for the FOLFIRI arm). Chi square tests were used to compare the characteristics of patients treated in L2 with those of patients who did not receive L2. Prognostic factors in L2 for progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox model. Results Among 416 patients included, 101/209 (48.3%) patients in the ECX arm received FOLFIRI in L2, and 81/207 (39.1%) patients in the FOLFIRI arm received ECX in L2. Patients treated in L2, compared with those who only received L1 had : a better ECOG score (0–1: 90.4% versus 79.7%; p = 0.0002), more frequent GEJ localization (40.8% versus 27.6%; p = 0.005), and lower platelet count (median: 298000 versus 335000/$ mm^{3} $; p = 0.02). In multivariate analyses, age < 60 years at diagnosis (HR 1.49, 95% CI 1.09–2.03, p = 0.013) and ECOG score 2 before L2 (HR 2.62, 95% CI 1.41–4.84, p = 0.005) were the only significant poor prognostic factors for OS. Conclusion Age ≥ 60 years at diagnosis and ECOG score 0/1 before L2 were the only favorable prognostic factors for OS.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastric neoplasm</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Survival</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prognosis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Second-line chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guimbaud, R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Louvet, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dahan, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Samalin, E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barbier, E.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Le Malicot, K.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cohen, R.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gornet, J. M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aparicio, T.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nguyen, S.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Azzedine, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Etienne, P. L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Phelip, J. M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hammel, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chapelle, N.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sefrioui, D.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mineur, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lepage, C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bouche, O.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Gastric Cancer</subfield><subfield code="d">Springer-Verlag, 2002</subfield><subfield code="g">22(2018), 3 vom: 11. Okt., Seite 577-586</subfield><subfield code="w">(DE-627)SPR009286586</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:22</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:3</subfield><subfield code="g">day:11</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:577-586</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10120-018-0885-z</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">22</subfield><subfield code="j">2018</subfield><subfield code="e">3</subfield><subfield code="b">11</subfield><subfield code="c">10</subfield><subfield code="h">577-586</subfield></datafield></record></collection>
|
| score |
7.399867 |